Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

28 June 2016  
SEBIA, SPECIALIST IN ELECTROPHORESIS WILL DISTRIBUTE WORLDWIDE SERALITE®– FLC SERUM LATERAL FLOW IMMUNOASSAYS FOR THE DIAGNOSIS AND MONITORING OF MULTIPLE MYELOMA
By @ 09:38 :: 29 Views

Paris, France, and York, UK, June 27, 2016 – Sebia, the world leader in medical diagnostics by electrophoresis, and Abingdon Health, an in-vitro diagnostic group, today announce that they have entered into a multi-year, exclusive, global distribution agreement. The deal allows Sebia to add Abingdon Health’s Seralite®– FLC Dual Kappa and Lambda serum lateral flow immunoassay to its worldwide offering. The financial terms of the agreement have not been disclosed.
Read More

24 June 2016  
AGM Statement and Result of AGM
By @ 14:08 :: 20 Views

 

24 June 2016

 

At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a therapeutic target in Alzheimer’s disease should increase interest in new treatments which could favourably affect our compounds targeting CK1d in the tau pathway. We are confident that the business remains on track in 2016 to deliver a significant increase in revenues.

Read More

22 June 2016  
Increased efficiency and faster viral load results with DxN VERIS Molecular Diagnostics System
By @ 09:16 :: 16 Views

Niguarda Hospital, Milan, shares experiences in newly available case study

 

Nyon, Switzerland — (21 June 2016)A newly released case study, available from Beckman Coulter, describes the experiences of Niguarda Hospital’s Molecular Biology Laboratory in the assessment of the DxN VERIS Molecular Diagnostics System.  Involving fewer steps and reagents, and with true, single sample random access, DxN VERIS increased laboratory efficiency and allowed faster turnaround of viral load results.

Read More

14 June 2016  
Study shows efficacy of Beckman Coulter DxN VERIS Molecular Diagnostics System for monitoring CMV-DNA in plasma samples
By @ 12:26 :: 38 Views

Nyon, Switzerland — (14 June 2016) Beckman Coulter is pleased to highlight results published in the Journal of Clinical Virology1 that show the company’s DxN VERIS VERIS CMV Assay is more sensitive, and the DxN VERIS Molecular Diagnostics System has greater ease-of-use benefits , than another commercially available testing system.

Read More

07 June 2016  
Excellent results reported for DxN VERIS Molecular Diagnostic System HIV-1 Assay at multiple centres across Europe
By @ 14:18 :: 48 Views


Nyon, Switzerland — (07 June 2016) Beckman Coulter is pleased to highlight the findings of a poster, presented at ECCMID, Amsterdam, 2016, regarding the analytical performance of the company’s fully automated DxN VERIS Molecular Diagnostics System and VERIS HIV-1 Assay

Read More

27 May 2016  
Multiplicom receives €1.9M grant to develop innovative liquid biopsy based cancer tests
By @ 14:00 :: 66 Views


Belgium, May 2016 - Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients. 

Read More

18 May 2016  
CEO Appointment
By @ 15:32 :: 57 Views


18 May 2016
Against the buoyant background and trajectory of the PS Biomarker Services business it is
now appropriate to expand the executive team with a senior figure strongly connected to
the pharmaceutical industry and to split the role of Executive Chairman.
Read More

18 May 2016  
Preliminary results for the year ended 31st December, 2015
By @ 09:21 :: 59 Views


18th May, 2016

 

Highlights

 

·         Turnover increased 20% to £1.88m (2014:£1.56m)

·         Licenses/Sales/Services revenue up 30% to £1.68m (2014:£1.30m)

-    Strong 51% growth in biomarker services

-    TMT® product sales rose 33% in 2015

-    Grant services £0.21m (2014: £0.27m)

·         Reduced loss after tax £2.72m (2014:£3.57m)

·         Cash at year-end £1.81m (2014:£1.87m)

·         Levels of SysQuant® /TMTcalibrator™ production doubled Q4

·         Compelling evidence in second in vivo study in Alzheimer’s that CK1d compounds reduce tau levels 

Read More

18 May 2016  
CEO Appointment
By @ 09:18 :: 61 Views


For immediate release: 18th May 2016; Cobham, UK.
Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.
Read More

16 May 2016  
OGT launches Cytocell FISH probes for glial tumours
By @ 12:37 :: 65 Views

Oxford, UK – 04 May 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours.  





Read More

Previous Page | Next Page